Sun Pharmaceutical Industries, India’s largest pharmaceutical company, has entered into a definitive agreement to acquire Organon in an all-cash transaction valuing the company at $11.75 billion enterprise value. Organon stockholders will receive $14.00 per share. The transaction is expected to close in early 2027.
Organon is one of the largest dedicated women’s health pharmaceutical companies globally, spun out of Merck (MSD outside the U.S.) in 2021 with a mission to deliver medicines that address health needs that uniquely, disproportionately, or differently affect women. Its portfolio includes more than 70 products across women’s health and general medicines (including biosimilars), commercialized across 140 countries. For the year ended December 2025, Organon reported $6.2 billion in revenue.
The deal positions the combined company as a top 3 player in global women’s health, with combined revenue of $12.4 billion and presence in 150 countries. Sun Pharma described the acquisition as aligned with its strategy of growing its innovative medicines business, and said the combined entity would create a commercial platform for future growth in women’s health.
“This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives,” said Sun Pharma executive chairman Dilip Shanghvi. “Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”
“Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders,” said Organon executive chair Carrie Cox. “We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions.”
The acquisition is the largest women’s health pharma deal in recent memory and will be closely watched across the sector. Organon was created specifically to be a women’s health-focused company, and its absorption into a broader generics and specialty pharma platform raises questions about whether that dedicated focus will be maintained, expanded, or diluted. Sun Pharma plans to fund the acquisition through available cash and committed bank financing.
